Free tool
FAERS Monitor: Agrylin
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 020333 or its brand name (Agrylin, Anagrelide Hydrochloride). Reports on generic versions are filed under their own applications.
Reports
1,175
Serious
946
81% of reports
Hospitalization
456
Death reported
128
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- off label use82
- anaemia63
- platelet count increased60
- cerebral infarction51
- headache46
- fatigue45
- diarrhoea42
- dizziness41
- myelofibrosis41
- haemoglobin decreased38
- nausea36
- asthenia34
- hypertension34
- palpitations33
- renal failure33
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 33 |
| 2005 | 42 |
| 2006 | 32 |
| 2007 | 22 |
| 2008 | 31 |
| 2009 | 18 |
| 2010 | 12 |
| 2011 | 58 |
| 2012 | 55 |
| 2013 | 17 |
| 2014 | 17 |
| 2015 | 34 |
| 2016 | 42 |
| 2017 | 72 |
| 2018 | 82 |
| 2019 | 105 |
| 2020 | 87 |
| 2021 | 80 |
| 2022 | 67 |
| 2023 | 100 |
| 2024 | 65 |
| 2025 | 66 |
| 2026 | 38 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,984 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| myelofibrosisSignal | 41 | 246.0 | 181.7 | 9,631 |
| platelet count increasedSignal | 60 | 82.8 | 64.6 | 4,746 |
| cerebral infarctionSignal | 51 | 37.4 | 28.6 | 1,771 |
| haemoglobin decreasedSignal | 38 | 6.6 | 4.8 | 177 |
| anaemiaSignal | 63 | 5.9 | 4.7 | 255 |
| palpitationsSignal | 33 | 5.0 | 3.6 | 104 |
| renal failureSignal | 33 | 4.4 | 3.2 | 85 |
| hypertensionSignal | 34 | 2.9 | 2.1 | 40 |
| off label use | 82 | 1.7 | 1.4 | 23 |
| asthenia | 34 | 1.6 | 1.2 | 8 |
| dizziness | 41 | 1.5 | 1.1 | 6 |
| headache | 46 | 1.3 | 1.0 | 3 |
| diarrhoea | 42 | 1.2 | 0.9 | 1 |
| fatigue | 45 | 1.0 | 0.8 | 0 |
| nausea | 36 | 0.8 | 0.6 | 1 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.